Journal of Surgical Research Article Details Positive Comparative Results for Miromatrix Medical’s MIROMESH® Product in Hernia Repair

Small Animal Study Demonstrates Superior Cellular Infiltration Compared to Strattice™
 

Miromatrix Medical Inc., a company engaged in the development of fully biological human organs for transplant, as well as a family of organ-derived biological mesh products based upon its proprietary perfusion decellularization/recellularization technology, announced today that the results of a pre-clinical study of its novel prosthetic (MIROMESH) derived from porcine liver by perfusion decellularization have been published in the Journal of Surgical Research.  These results mark the first in a series of small animal, large animal and human studies completed or underway describing the use of MIROMESH for hernia repair.

The study, conducted by Drs. Michael J. Rosen (currently at the Cleveland Clinic), Clayton C. Petro, Ajita S. Prabhu, Lijia Liu, and Arnab Majumber of University Hospitals Case Medical Center, compared MIROMESH to a popular non-crosslinked decellularized porcine dermal biomesh (Strattice) in an established model of hernia repair.  The study concluded, as first presented at the 2015 Abdominal Wall Reconstruction Conference in Washington D.C., that “MIROMESH demonstrated a superior degree of cellular infiltration with equivalent clearance of a bacterial inoculum compared to Strattice.”

Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world.  MIROMESH is the first product commercialized based upon this technology, and has been cleared by the U.S. FDA and implanted by surgeons across the United States for more than one year. 

“It is exciting to see such positive results from the first published evaluation of MIROMESH,” said Robert Cohen, President & CEO of Miromatrix.  “We are honored to have been able to work with such esteemed investigators as we pursue our strong emphasis on science-based products and results-based confirmation in the first of many areas that we intend to enter with our cutting edge technology.”